Search results for "DISEASE PROGRESSION"

showing 10 items of 835 documents

SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B

2014

A proper balance between saturated and unsaturated fatty acids (FAs) is required for maintaining cell homeostasis. The increased demand of FAs to assemble the plasma membranes of continuously dividing cancer cells might unbalance this ratio and critically affect tumour outgrowth. We unveiled the role of the stearoyl-CoA desaturase SCD5 in converting saturated FAs into mono-unsaturated FAs during melanoma progression. SCD5 is down-regulated in advanced melanoma and its restored expression significantly reduced melanoma malignancy, both in vitro and in vivo, through a mechanism governing the secretion of extracellular matrix proteins, such as secreted protein acidic and rich in cysteine (SPAR…

cathepsin B2734Intracellular SpaceDown-RegulationCell LineMelanocyteCell Line TumormelanomaHumansintracellular acidityOsteonectinNeoplasticTumorMedicine (all)Fatty AcidsSPARCHydrogen-Ion ConcentrationGene Expression Regulation NeoplasticSCD5Gene Expression Regulationoleic acidDisease ProgressionMelanocytesFatty AcidStearoyl-CoA Desaturasecathepsin B; intracellular acidity; melanoma; oleic acid; SCD5; SPARC; Cathepsin B; Cell Line Tumor; Disease Progression; Down-Regulation; Fatty Acids; Humans; Hydrogen-Ion Concentration; Intracellular Space; Melanocytes; Melanoma; Oleic Acid; Osteonectin; Stearoyl-CoA Desaturase; Gene Expression Regulation Neoplastic; 2734; Medicine (all)Human
researchProduct

Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations

2020

Patients with transthyretin amyloid polyneuropathy (TTR-FAP) and asymptomatic mutation-carriers have to be regularly followed-up in order to identify disease progression and the time point for starting or modifying therapy. In this case series we describe the potential suitability of different variables as progression markers. We retrospectively analyzed the follow-up charts of 10 TTR-FAP patients. Clinical examination included the Neuropathy Impairment Score of Lower Limb (NIS-LL), temperature perception thresholds, nerve conduction and autonomic function tests. The NIS-LL had the greatest value for a sensitive and correct follow-up for all TTR-FAP stages. All other examinations provided u…

congenital hereditary and neonatal diseases and abnormalitiesendocrine systemmedicine.medical_specialtyNeural ConductionPhysical examinationAsymptomatic03 medical and health sciences0302 clinical medicineClinical investigationInternal medicinemedicineHumansPrealbumin030212 general & internal medicineRetrospective StudiesAmyloid Neuropathies Familialbiologymedicine.diagnostic_testbusiness.industryAmyloidosisDisease progressionnutritional and metabolic diseasesmedicine.diseasedigestive system diseasesTransthyretinNeurologybiology.proteinAmyloid polyneuropathyNeurology (clinical)medicine.symptombusinessPolyneuropathy030217 neurology & neurosurgeryFollow-Up StudiesJournal of the Neurological Sciences
researchProduct

Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus

2003

Background— To investigate early events possibly related to the development of diabetic angiopathy, we examined whether 8-iso-prostaglandin F 2α (8-iso-PGF 2α ) formation, a marker of in vivo oxidant stress, is altered in different stages of type 1 diabetes (T1DM) and whether it correlates with the rate of thromboxane (TX) A 2 biosynthesis, a marker of in vivo platelet activation. We also investigated the relationship between inflammatory markers and F 2 -isoprostane formation in this setting. Methods and Results— A cross-sectional study was performed in 23 insulin-treated patients aged <18 years with new-onset T1DM (≤6 weeks, group A), matched for age and gender with 23 patients with s…

diabetes mellitus; inflammation; plateletsMalemedicine.medical_specialtyAdolescentThromboxaneInflammationDiabetic angiopathyDinoprostTimeThromboxane A2Reference ValuesPhysiology (medical)Internal medicineDiabetes mellitusHumansInsulinMedicinePlatelet activationChildInterleukin 6InflammationF2-IsoprostanesType 1 diabetesbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryPlatelet Activationmedicine.diseaseThromboxane B2Oxidative StressC-Reactive ProteinCross-Sectional StudiesDiabetes Mellitus Type 1Endocrinologydiabetes mellitusplateletsDisease Progressionbiology.proteinFemaleTumor necrosis factor alphaLipid Peroxidationmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesCirculation
researchProduct

Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis

2019

\(\bf Objective:\) The autoimmune disease Multiple Sclerosis (MS) represents a heterogeneous disease pattern with an individual course that may lead to permanent disability. In addition to immuno-modulating therapies patients benefit from symptomatic approaches like intrathecal corticosteroid therapy (ICT), which is frequently applied in a growing number of centers in Germany. ICT reduces spasticity, which elongates patient's walking distance and speed, thus improves quality of life. \(\bf Methods:\) In our study we set out to investigate cerebrospinal fluid (CSF) parameters and clinical predictors for response to ICT. Therefore, we analyzed 811 CSF samples collected from 354 patients over …

disease progressionNeurologyclinical predictorparasitic diseasesintrathecal corticosteroid therapyddc:610multiple sclerosiscerebrospinal fluidlcsh:Neurology. Diseases of the nervous systemlcsh:RC346-429Original ResearchFrontiers in Neurology
researchProduct

Expression of tenascin in human cervical cancer--association of tenascin expression with clinicopathological parameters.

1999

Tenascin is an extracellular matrix glycoprotein, relevant for embryonal and fetal development, which is reexpressed in the stroma of benign and malignant tumors. Little is known about the molecular interaction of tenascin during neoplastic transformation and tumor progression in cervical cancer.We studied the expression of tenascin in normal tissue of the cervix uteri, cervical carcinoma in situ, and invasive cervical carcinoma in paraffin sections by immunohistochemistry using a monoclonal antibody. Tenascin immunoreactivity was compared with various prognostic parameters.In normal cervical tissue (n = 5) and in cervical carcinoma in situ (n = 10) only vessel walls showed a weak tenascin …

endocrine systemPathologymedicine.medical_specialtyanimal structuresStromal cellConnective tissueTenascinUterine Cervical NeoplasmsMalignant transformationmedicineHumansNeoplastic transformationCervixRetrospective Studiesbiologybusiness.industryObstetrics and GynecologyTenascinmusculoskeletal systemPrognosisImmunohistochemistrySurvival Ratemedicine.anatomical_structureOncologyTumor progressionembryonic structuresbiology.proteinDisease ProgressionImmunohistochemistryFemalebusinessCarcinoma in SituGynecologic oncology
researchProduct

EZH2 mutations are frequent and represent an early event in follicular lymphoma

2013

Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2 mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27% of FL cases with variant allele frequencies (VAF) ranging from 2% to 61%. By comparing VAF of EZH2 with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harbori…

endocrine systemTime FactorsMethyltransferasemedicine.medical_treatmentDNA Mutational AnalysisImmunologyFollicular lymphomaKaplan-Meier Estimatemacromolecular substancesBiologymedicine.disease_causeBiochemistryTargeted therapyCohort StudiesGene Frequencyhemic and lymphatic diseasesBiomarkers TumormedicineHumansEnhancer of Zeste Homolog 2 ProteinLymphoma FollicularAllele frequencyMutationLymphoid NeoplasiaMEF2 Transcription FactorsGene Expression ProfilingEZH2Polycomb Repressive Complex 2Germinal centerCell BiologyHematologymedicine.diseaseCREB-Binding ProteinLymphomaMutationDisease ProgressionCancer researchReceptors Tumor Necrosis Factor Member 14Blood
researchProduct

Time to ferry heart failure onto new shores: The need to effectively customize long-term therapy

2011

heart failure therapymedicine.medical_specialtybusiness.industryTreatment outcomeDisease progressionMEDLINEmedicine.diseaseHeart failureInternal medicinemedicineCardiologyLong term therapyCardiology and Cardiovascular MedicineIntensive care medicinebusinessAmerican Heart Journal
researchProduct

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized …

2008

Summary Purpose A phase III randomized trial was carried out to compare two schedules of the vinorelbine (VNR)–cisplatin (CDDP) regimen in patients with locally advanced unresectable poor prognosis stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL). Patients and methods Eligible patients were randomized to receive: (a) VNR 25 mg/m 2 on day 1, 8 and 15 plus CDDP 100 mg/m 2 on day 1 every 4 weeks or (b) VNR 30 mg/m 2 on day 1 and 8 plus CDDP 80 mg/m 2 on day 1 every 3 weeks. All patients were chemotherapy-n…

inorganic chemicalsPulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyRandomizationLung NeoplasmsVinorelbineVinblastineGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerProspective cohort studyneoplasmsAgedNeoplasm StagingChi-Square Distributionbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineSurgeryRegimenLogistic ModelsTreatment OutcomeOncologyItalyDisease ProgressionQuality of LifeFemaleCisplatinbusinessFebrile neutropeniamedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report

2012

Abstract Background Fabry disease (FD) is a hereditary metabolic disorder caused by the partial or total inactivation of a lysosomal hydrolase, the enzyme α-galactosidase A (GLA). This inactivation is responsible for the storage of undegraded glycosphingolipids in the lysosomes with subsequent cellular and microvascular dysfunction. The incidence of disease is estimated at 1:40,000 in the general population, although neonatal screening initiatives have found an unexpectedly high prevalence of genetic alterations, up to 1:3,100, in newborns in Italy, and have identified a surprisingly high frequency of newborn males with genetic alterations (about 1:1,500) in Taiwan. Case presentation We des…

lcsh:Diseases of the circulatory (Cardiovascular) systemPathologyα-galactosidase AAnderson-Fabry mutationBiopsyDNA Mutational AnalysisCase Reportmedicine.disease_causeGlobotriaosylceramide0302 clinical medicineSettore BIO/13 - Biologia ApplicataPromoter Regions Genetic0303 health sciencesMutationeducation.field_of_studymedicine.diagnostic_testbiologyMetabolic disorderMagnetic Resonance Imaging3. Good healthPhenotypeCardiovascular DiseasesDisease ProgressionFemaleKidney DiseasesRenal biopsyCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulation03 medical and health sciencesPredictive Value of TestsBiopsymedicineHumansHigh resolution meltingGenetic Predisposition to Diseaseeducation030304 developmental biologyFabry diseaseAlpha-galactosidasebusiness.industrymedicine.diseaseFabry diseaseIntronslcsh:RC666-701alpha-GalactosidaseMutationGLAbiology.proteinbusiness030217 neurology & neurosurgeryKidney disease
researchProduct

Prevalence and morphometric analysis of the retromolar canal in a Spanish population sample: a helical CT scan study.

2021

BACKGROUND: The retromolar canal (RMC) is an anatomical variation of the mandibular canal (MC) whose identification and study should be considered given its implication in the surgical procedures of the retromolar area. The prevalence of the RMC widely varies according to previous studies and may be influenced by the followed study method. This work aimed to evaluate the prevalence of the RMC in a Spanish population sample. MATERIAL AND METHODS: For this purpose, 225 CT scan images (with a higher resolution than the cone beam CT used in other previous studies) from the Hospital Clinico Universitario de Valencia were analyzed. The Osirix MD radiological image analysis system was applied to a…

locoregional recurrencehpv-16Mandibular canalMandiblesurvivaldisease progressionmedicinePrevalenceHumanshuman papillomavirusGeneral DentistryCone beam ctUNESCO:CIENCIAS MÉDICASOrthodonticshpvbusiness.industryAnatomic VariationSurgical proceduresCone-Beam Computed Tomographyoral cancerHelical ctClinical PracticeSpanish populationoral squamous cell carcinomamedicine.anatomical_structureOtorhinolaryngologyMorphometric analysisRadiological weaponSurgerybusinessTomography Spiral Computed
researchProduct